TY - JOUR T1 - PKP-022 The KCNMB1 (A >G) (RS703505) genetic variant and the efficacy of tocilizumab in rheumatoid arthritis patients JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - A188 LP - A188 DO - 10.1136/ejhpharm-2016-000875.425 VL - 23 IS - Suppl 1 AU - X Díaz-Villamarín AU - CL Dávila-Fajardo AU - MDC Gónzalez-Medina AU - MJ Soto-Pino AU - E Sánche-Gómez AU - A Acuña AU - A Gómez-Martín AU - LJ Martínez-González AU - I Casas-Hidalgo AU - J Cabeza-Barrera Y1 - 2016/03/01 UR - http://ejhp.bmj.com/content/23/Suppl_1/A188.2.abstract N2 - Background Tocilizumab (TCZ) is a humanised monoclonal antibody inhibitor of interleukin-6 receptor, indicated in combination with methotrexate in the treatment of rheumatoid arthritis (RA) in patients with inadequate response or intolerance to prior therapy.Purpose The aim of our study was to explore the potential role of KCNMB1 genetic polymorphisms as a predictor of tocilizumab efficacy in RA patients.Material and methods The KCNMB1 (A >G) (rs703505) genetic variant was genotyped using predesigned TaqMan genotyping assay technology and analysed on a ViiA7 real time PCR system. Clinical response was evaluated at 24 weeks with the use of the 28 joint disease activity score criteria (DAS28). Clinical response was evaluated at 14 weeks using DAS28 and good response and remission were classified according to EULAR criteria. EULAR good response was defined as a change in DAS28 >1.2 and DAS28 ≤3.2. EULAR remission was defined as DAS28 ≤2.6 at 14 weeks. Statistical analysis was performed using SPSS v.20.Results Clinical data for 140 tocilizumab treated patients were obtained. Patients were aged (mean±SD) 53.25 ± 12.42 years; 79% were female. Mean DAS28 at baseline was 5.71 ± 1.13. KCNMB1-GG genetic polymorphism was associated with EULAR good response (GG vs no GG p = 0.26, OR=0.37, 95% CI 0.14 to 0.93) and with EULAR remission (p = 0.01, OR=0.29, 95% CI 0.09 to 0.87).Conclusion Our results confirm that KCNMB1 (A >G) rs703505 polymorphisms could be useful as a genetic marker of tocilizumab efficacy in RA patients. More studies are necessary to confirm these results.No conflict of interest. ER -